Alvotech's Manufacturing Progress, Simponi Launch Potential Support Recovery, UBS Says

MT Newswires Live00:11

Alvotech (ALVO) has meaningful stock recovery potential as manufacturing progress boosts confidence and regulatory uncertainty eases, UBS Securities said in a note previewing the company's Q3 results.

The company is scheduled to report its Q3 results on Nov. 12.

The FDA's approval of additional manufacturing capacity for Simlandi, Alvotech's biosimilar to Humira, validates improvements at its Reykjavik site and provides a positive signal ahead of pending FDA decisions in December, UBS said in a Monday note.

Alvotech and Teva Pharmaceuticals (TEVA) could launch their Simponi biosimilar in the US following FDA approval, potentially at risk amid pending litigation with Johnson & Johnson (JNJ). The brokerage said that J&J faces a low likelihood of securing a preliminary injunction.

The brokerage identified FDA approvals and a potential launch of the Simponi biosimilar as key catalysts for unlocking value. It also highlighted continued manufacturing capacity expansion through internal investment and external partnerships.

UBS reiterated its buy rating on Alvotech and raised its price target to $8 from $6, citing improved sales expectations for its existing Humira and Stelara biosimilars and greater confidence in the durability of the portfolio.

Shares of Alvotech were up 3.2% in Tuesday afternoon trading.

Price: 5.19, Change: +0.16, Percent Change: +3.18

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2677697002?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-21 00:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2677697002","market":"fut","top_or_hot":-1,"title":"Alvotech's Manufacturing Progress, Simponi Launch Potential Support Recovery, UBS Says","media":"MT Newswires Live","content":"<html><body><p> Alvotech (ALVO) has meaningful stock recovery potential as manufacturing progress boosts confidence and regulatory uncertainty eases, UBS Securities said in a note previewing the company's Q3 results.</p><p>The company is scheduled to report its Q3 results on Nov. 12.</p><p>The FDA's approval of additional manufacturing capacity for Simlandi, Alvotech's biosimilar to Humira, validates improvements at its Reykjavik site and provides a positive signal ahead of pending FDA decisions in December, UBS said in a Monday note.</p><p>Alvotech and <a href=\"https://laohu8.com/S/TEVA\">Teva</a> Pharmaceuticals (TEVA) could launch their Simponi biosimilar in the US following FDA approval, potentially at risk amid pending litigation with Johnson &amp; Johnson (JNJ). The brokerage said that J&amp;J faces a low likelihood of securing a preliminary injunction.</p><p>The brokerage identified FDA approvals and a potential launch of the Simponi biosimilar as key catalysts for unlocking value. It also highlighted continued manufacturing capacity expansion through internal investment and external partnerships.</p><p>UBS reiterated its buy rating on Alvotech and raised its price target to $8 from $6, citing improved sales expectations for its existing Humira and Stelara biosimilars and greater confidence in the durability of the portfolio.</p><p>Shares of Alvotech were up 3.2% in Tuesday afternoon trading.</p><p>Price: 5.19, Change: +0.16, Percent Change: +3.18</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alvotech's Manufacturing Progress, Simponi Launch Potential Support Recovery, UBS Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlvotech's Manufacturing Progress, Simponi Launch Potential Support Recovery, UBS Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-10-21 00:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Alvotech (ALVO) has meaningful stock recovery potential as manufacturing progress boosts confidence and regulatory uncertainty eases, UBS Securities said in a note previewing the company's Q3 results.</p><p>The company is scheduled to report its Q3 results on Nov. 12.</p><p>The FDA's approval of additional manufacturing capacity for Simlandi, Alvotech's biosimilar to Humira, validates improvements at its Reykjavik site and provides a positive signal ahead of pending FDA decisions in December, UBS said in a Monday note.</p><p>Alvotech and <a href=\"https://laohu8.com/S/TEVA\">Teva</a> Pharmaceuticals (TEVA) could launch their Simponi biosimilar in the US following FDA approval, potentially at risk amid pending litigation with Johnson &amp; Johnson (JNJ). The brokerage said that J&amp;J faces a low likelihood of securing a preliminary injunction.</p><p>The brokerage identified FDA approvals and a potential launch of the Simponi biosimilar as key catalysts for unlocking value. It also highlighted continued manufacturing capacity expansion through internal investment and external partnerships.</p><p>UBS reiterated its buy rating on Alvotech and raised its price target to $8 from $6, citing improved sales expectations for its existing Humira and Stelara biosimilars and greater confidence in the durability of the portfolio.</p><p>Shares of Alvotech were up 3.2% in Tuesday afternoon trading.</p><p>Price: 5.19, Change: +0.16, Percent Change: +3.18</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE000WAW04H5.SGD","symbol_name":"RQI GLOBAL \"I\" (SGD) INC A","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2677697002","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2677697002","pubTimestamp":1792512708,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Alvotech  has meaningful stock recovery potential as manufacturing progress boosts confidence and regulatory uncertainty eases, UBS Securities said in a note previewing the company's Q3 results.The company is scheduled to report its Q3 results on Nov. 12.The FDA's approval of additional manufacturing capacity for Simlandi, Alvotech's biosimilar to Humira, validates improvements at its Reykjavik site and provides a positive signal ahead of pending FDA decisions in December, UBS said in a Monday note.Alvotech and Teva Pharmaceuticals  could launch their Simponi biosimilar in the US following FDA approval, potentially at risk amid pending litigation with Johnson & Johnson . The brokerage said that J&J faces a low likelihood of securing a preliminary injunction.The brokerage identified FDA approvals and a potential launch of the Simponi biosimilar as key catalysts for unlocking value. It also highlighted continued manufacturing capacity expansion through internal investment and external pa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE000WAW04H5.SGD":"RQI GLOBAL \"I\" (SGD) INC A","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","BBP":"Virtus LifeSci Biotech Products ETF","LU0553294199.USD":"BGF GLOBAL EQUITY INCOME \"A5G\" (USD) INC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","PRGS":"Progress Software Corporation","IYH":"iShares U.S. Healthcare ETF","IHE":"iShares U.S. Pharmaceuticals ETF","BMED":"iShares Health Innovation Active ETF","LABU":"三倍做多标普生物-Direxion","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","GDOC":"Goldman Sachs Future Health Care Equity ETF","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","TEVA":"梯瓦制药","IE0001KFT4U8.USD":"FTGF CLEARBRIDGE GLOBAL GROWTH LEADERS \"A\" (USD) INC","LU0964807845.USD":"ALLIANZ INCOME & GROWTH \"A\" (USD) INC","TRUH":"VanEck Healthcare TruSector ETF","LU1032955483.USD":"NORDEA 1 STABLE RETURN \"HB\" (USDHDG) ACC","IXJ":"全球医疗业ETF-iShares","LU1629891620.HKD":"ALLIANZ INCOME AND GROWTH \"AMG2\" (H2-HKD) INC","XLV":"健康照护类股ETF-SPDR","BK4568":"美国抗疫概念","ALVO":"Alvotech","FHLC":"Fidelity MSCI Health Care Index","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0210536198.USD":"JPM US GROWTH \"A\" ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","LU2430703095.HKD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (HKD) INC","JNJ":"强生","LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","MEDX":"HORIZON KINETICS MEDICAL ETF","LU1778281490.HKD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (HKD) INC","RXL":"ProShares Ultra Health Care","JDOC":"JPMORGAN HEALTHCARE LEADERS ETF","VHT":"Vanguard Health Care ETF","BK4532":"文艺复兴科技持仓","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0994945656.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) INC 2","LU2023250330.USD":"ALLIANZ INCOME AND GROWTH \"AMG\" (USD) INC","FTXH":"First Trust Nasdaq Pharmaceuticals ETF","BK4584":"避孕概念","LU0545562505.USD":"NINETY ONE GSF GLOBAL QUALITY DIVIDEND GROWTH \"A\" (USD) INC","PJP":"INVESCO PHARMACEUTICALS ETF"},"translate_title":"瑞银表示，Alvotech 的制造进展和 Simponi 推出潜在支持复苏","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GDOC":0.6,"ALVO":1,"PRGS":1.5,"IHE":0.6,"PJP":0.6,"MEDX":0.6,"TEVA":1,"RXL":0.6,"FHLC":0.6,"IXJ":0.6,"JDOC":0.6,"XLV":0.6,"FTXH":0.6,"JNJ":1,"VHT":0.6,"IYH":0.6,"BMED":0.6,"LABU":0.62,"BBP":0.78,"TRUH":0.6},"content_text":"Alvotech (ALVO) has meaningful stock recovery potential as manufacturing progress boosts confidence and regulatory uncertainty eases, UBS Securities said in a note previewing the company's Q3 results.The company is scheduled to report its Q3 results on Nov. 12.The FDA's approval of additional manufacturing capacity for Simlandi, Alvotech's biosimilar to Humira, validates improvements at its Reykjavik site and provides a positive signal ahead of pending FDA decisions in December, UBS said in a Monday note.Alvotech and Teva Pharmaceuticals (TEVA) could launch their Simponi biosimilar in the US following FDA approval, potentially at risk amid pending litigation with Johnson & Johnson (JNJ). The brokerage said that J&J faces a low likelihood of securing a preliminary injunction.The brokerage identified FDA approvals and a potential launch of the Simponi biosimilar as key catalysts for unlocking value. It also highlighted continued manufacturing capacity expansion through internal investment and external partnerships.UBS reiterated its buy rating on Alvotech and raised its price target to $8 from $6, citing improved sales expectations for its existing Humira and Stelara biosimilars and greater confidence in the durability of the portfolio.Shares of Alvotech were up 3.2% in Tuesday afternoon trading.Price: 5.19, Change: +0.16, Percent Change: +3.18","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2677697002","isCrawlerRequest":true}